Cortexyme, Inc. is a clinical stage biopharmaceutical company. The Company is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company is focused on an infectious pathogen tied to neurodegeneration and chronic inflammation in humans and animal models. The Company's lead drug candidate, COR388, is an orally administered, brain-penetrating small molecule gingipain inhibitor designed for the treatment of Alzheimer's disease. COR388 is designed to target an upstream driver of multiple Alzheimer's pathological pathways, including amyloid beta production, inflammation and neurodegeneration, in contrast to mechanisms of action targeting downstream effects, such as amyloid plaques and tau tangles. It is also developing COR588, is a second-generation brain penetrant lysine gingipain inhibitor. COR788 and COR822 are arginine gingipain inhibitors with therapeutic potential in Porphyromonas gingivalis (P. gingivalis) related diseases.